Filter Specialty
Filterspecialty
Submit To The Journals
Previous
Article
Next
Article

Plasma matrix metalloproteinases in neonates having surgery for congenital heart disease

Heart International 2009;4(1):e4 https://doi.org/10.4081/hi.2009.e4

Abstract

During cardiopulmonary-bypass matrixmetalloproteinases released may contribute to ventricular dysfunction. This study was to determine plasma matrix-metalloproteinases in neonates after cardiopulmonary-bypass and their relation to post-operative course. A prospective observational study included 18 neonates having cardiac surgery. Plasma matrix-metalloproteinases-2 and 9 activities were measured by gelatin-zymography preoperatively, on starting cardiopulmonarybypass, 7-8 min after aortic cross-clamp release, and 1h, 4h, 24h, and 3d after cardiopulmonary- bypass. Plasma concentrations of their tissue inhibitors 1 and 2 were determined by enzyme-linked immunosorbent assay. Cardiac function was assessed by serial echocardiography. Paired t-tests and Wilcoxon tests were used to assess temporal changes, and linear correlation with simultaneous clinical and cardiac function parameters were assessed using Pearson’s product-moment correlation coefficient. Plasma matrix-metalloproteinases activities and their tissue inhibitor concentrations decreased during cardiopulmonary-bypass. Matrix-metalloproteinase- 2 plasma activity increased progressively starting 1h after cardiopulmonarybypass and returned to pre-operative levels at 24h. Matrix-metalloproteinase-9 plasma activity increased significantly after release of aortic cross-clamp, peaked 7-8min later, and returned to baseline at 24h. Plasma tissueinhibitor 1 and 2 concentrations increased 1h after cardiopulmonary-bypass. Cardiac function improved from 4h to 3d after surgery (p<0.05). There was no evidence of significant correlations between matrix-metalloproteinases or their inhibitors and cardiac function, inotrope scores, organ dysfunction scores, ventilation days, or hospital days. The temporal profile of plasma matrix-metalloproteinases and their inhibitors after cardiopulmonary- bypass in neonates are similar to adults. In neonates, further study should determine whether circulating matrix-metalloproteinases are useful biomarkers of disease activity locally within the myocardium, and hence of clinical outcomes.

Keywords

Cardiopulmonary bypass, congenital heart disease, matrix metalloproteinases; neonate, pediatrics.

Acknowledgements

We thank the Pediatric Intensive Care Research Team for help with patient enrolment, and data and sample collection. We also thank Yuanyuan Liang and Quili Duan for assistance in statistical analyses. This project was supported by a grant from the University Hospital Foundation (AJ and PYC) and operating grants from the Canadian Institutes of Health Research (RS and PYC). RR, RS, and P-YC are researchers supported by the Alberta Heritage Foundation for Medical Research.

Received

March 24, 2009

Accepted

2009-05-15T00:00:00

Published Online

December 01, 2009

Correspondence

Ari R. Joffe, Department of Pediatrics, 3A3.07 Walter C Mackenzie Center, 8440-112 Street, Edmonton, Alberta, T6G 2B7 Canada. E-mail: ajoffe@cha.ab.ca

  • Touch Medical Media Limited, trading as Touch Medical Media, is a private limited company registered in England and Wales at The White House, Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142. © 2019 All rights reserved.

    touchcardio is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.